Photo of Mary Linton B Peters,  MD, MS

Mary Linton B Peters, MD, MS

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2100
Fax: (617) 975-5665


mbpeters@bidmc.harvard.edu

Mary Linton B Peters, MD, MS

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Staff Physician, Gastrointestinal Oncology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My initial academic and professional experience was in decision analysis and disease modeling, first at Stanford and then at Strategic Decisions Group. In recognition of this expertise, I was elected Fellow of the Society of Decision Professionals. As part of my medical training, I have gained experience in clinical research and health outcomes modeling, including dedicated research training during medical school and residency, and Harvard Catalyst courses in biostatistics and grant writing. I was selected to attend the AACR/ASCO Methods in Clinical Cancer Research workshop, developing a Phase 2 protocol in cholangiocarcinoma. I have been working with MGH’s Institute for Technology Assessment (ITA) since 2015. Mentored by Dr Pari Pandharipande, the Director of the ITA, we have developed a model of MRI screening strategies for first-degree family members of pancreatic ductal adenocarcinoma (PDAC) patients, the basis for my current research into the cost-effectiveness of germline genetic testing in this disease. In March 2020 I was awarded a K08 to support this work. Upon completion of fellowship in June 2017, I joined the faculty at BIDMC in the Medical Oncology division, with a clinical focus in GI Oncology and specifically hepatobiliary and pancreatic malignancies. In early 2020 I was promoted to Assistant Professor and became a senior scientist at the ITA. I am DF/HCC lead PI for 4 clinical trials and Site PI for 12 clinical trials largely in hepatobiliary cancers.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Peters MLB, Eckel A, Seguin CL, Davidi B, Howard DH, Knudsen AB, Pandharipande PV. Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations. JCO Oncol Pract 2023. PubMed
  • Pappas L, Baiev I, Reyes S, Bocobo AG, Jain A, Spencer K, Le TM, Rahma OE, Maurer J, Stanton J, Zhang K, De Armas AD, Deleon TT, Roth M, Peters MLB, Zhu AX, Boyhen K, VanCott C, Patel T, Roberts LR, Lindsey S, Horick N, Lennerz JK, Iafrate AJ, Goff LW, Mody K, Borad MJ, Shroff RT, Javle MM, Kelley RK, Goyal L. The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma. JCO Precis Oncol 2023; 7:e2200594. PubMed
  • Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. Journal of the National Cancer Institute 2023; 115:870-880. PubMed
  • Avigan ZM, Paredes R, Boussi LS, Lam BD, Shea ME, Weinstock MJ, Peters MLB. Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves. Cancer Med 2023. PubMed
  • Chhatwal J, Hajjar A, Mueller PP, Nemutlu G, Kulkarni N, Peters MLB, Kanwal F. Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals. Clin Gastroenterol Hepatol 2023. PubMed
  • Paredes de la Fuente R, Anderson ME, Peters MLB. Primary Undifferentiated Neoplasm of the Left Arm with Characteristics of Extragonadal Germ Cell Tumor and High-Grade Sarcoma. Clin Oncol Case Rep 2023. PubMed
  • Peters MLB, Eckel A, Lietz A, Seguin C, Mueller P, Hur C, Pandharipande PV. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. Pancreatology 2022. PubMed
  • Mueller PP, Chen Q, Ayer T, Nemutlu GS, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. J Hepatol 2022. PubMed
  • Grossman JE, Muthuswamy L, Huang L, Akshinthala D, Perea S, Gonzalez RS, Tsai LL, Cohen J, Bockorny B, Bullock AJ, Schlechter B, Peters MLB, Conahan C, Narasimhan S, Lim C, Davis RB, Besaw R, Sawhney MS, Pleskow D, Berzin TM, Smith M, Kent TS, Callery M, Muthuswamy SK, Hidalgo M. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. Clin Cancer Res 2021. PubMed
  • Tramontano AC, Chen Y, Watson TR, Eckel A, Sheehan DF, Peters MLB, Pandharipande PV, Hur C, Kong CY. Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013. Medicine (Baltimore) 2019; 98:e18082. PubMed
  • Weaver DT, Lietz AP, Mercaldo SF, Peters MLB, Hur C, Kong CY, Wolpin BM, Megibow AJ, Berland LL, Knudsen AB, Pandharipande PV. Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. AJR Am J Roentgenol 2019; 212:596-601. PubMed
  • Peters MLB, Stobie L, Dudley B, Karloski E, Allen K, Speare V, Dolinsky JS, Tian Y, DeLeonardis K, Krejdovsky J, Button A, Lim C, Borazanci E, Brand R, Tung N. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. Cancer 2019; 125:2488-2496. PubMed
  • Peters MLB, Eckel A, Mueller PP, Tramontano AC, Weaver DT, Lietz A, Hur C, Kong CY, Pandharipande PV. Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Pancreatology 2018. PubMed
  • Brand R, Borazanci E, Speare V, Dudley B, Karloski E, Peters MLB, Stobie L, Bahary N, Zeh H, Zureikat A, Hogg M, Lee K, Tsung A, Rhee J, Ohr J, Sun W, Lee J, Moser AJ, DeLeonardis K, Krejdovsky J, Dalton E, LaDuca H, Dolinsky J, Colvin A, Lim C, Black MH, Tung N. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer 2018; 124:3520-3527. PubMed
  • Peters ML, Tseng JF, Miksad RA. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clin Ther 2016. PubMed
Hide